在纽约与ST-升高心肌梗塞有关的心脏性休克的当代管理:一个多中心注册表
Abduljabar Adi1,2,3, Ramsis Ramsis1,3, Emily Rodriguez1,3
1Northwell, New Hyde Park, New York.
Journal of the Society for Cardiovascular Angiography & Interventions
|November 21, 2025
概括
早期的再血管化对于ST升高心肌梗塞相关心脏病性休克 (STEMI-CS) 的存活至关重要. 尽管纽约的侵入性治疗率很高,但风险厌恶会影响STEMI-CS患者的延期决定.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 临界护理医学 临界护理医学
背景情况:
- 早期的再血管化显著改善了ST升高心肌梗塞相关心脏病性休克 (STEMI-CS) 的存活率.
- 在公开结果报告的州,STEMI-CS的侵入性管理率似乎更低.
- 在STEMI-CS中侵袭性策略使用不足的原因尚不清楚.
研究的目的:
- 报告纽约队列中STEMI-CS的当代治疗模式.
- 检查推迟对STEMI-CS患者的侵入性治疗的原因.
- 确定与保守的管理策略相关的因素.
主要方法:
- 追溯分析诺斯韦尔冲击登记 (2016年1月至2022年8月).
- 包括纽约11家医院的所有STEMI-CS患者.
- 侵入性和保守管理组之间的临床变量和结果的比较.
- 手动收集推迟原因和多变量后勤回归分析.
主要成果:
- 在87%的STEMI-CS患者中使用了侵入性治疗.
- 穿皮冠状动脉干预 (PCI) 在63%的患者中进行,冠状动脉旁路移植 (CABG) 在8%的患者中进行.
- 在入侵治疗中,医院死亡率为27%,而在保守治疗中为81%.
- 延期的主要原因包括不明的神经状况 (35%),患者偏好 (29%) 和并发症 (25%).
- 与保守管理相关的因素包括年龄较大,肌素水平较高,心脏骤停和较高的SCAI阶段.
结论:
- 纽约的STEMI-CS当代侵入性治疗率很高.
- 风险厌恶似乎有助于推迟大量STEMI-CS患者的侵入性手术.
- 对STEMI-CS管理的决策过程进行进一步调查是有必要的.
相关概念视频
Myocarditis III: Medical Management
346
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
346
Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies
502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
Acute Coronary Syndrome IV: Interprofessional Care
528
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
528
Acute Coronary Syndrome V: Nursing Management
625
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
625
Cardiopulmonary Resuscitation IV: Pharmacological Management
1.7K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K


